{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:55:18Z","timestamp":1779357318862,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Malignancy-related ascites (MRA) is a common serious complication of many advanced malignant tumors with high morbidity and mortality. The high hospital expenditures induced by unplanned readmission in patients with MRA have become an urgent issue to the public. We aimed to overall assess the unplanned early readmission rate of patients with MRA and explore the potential risk factors for such readmission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study based on 2018 Nationwide Readmissions Database was performed and patients with MRA were recruited into the analysis. The primary outcome was unplanned 30-day readmission rate and inpatient outcomes. The multivariate logistic regression analysis was performed to evaluate the potential risk factors for such early readmission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data obtained from 32,457 patients with MRA were analyzed, and of these 7,799 individuals (24.03%) were unplanned readmitted within 30-day follow-up. The mortality rate in the readmitted population was 15.15%. Patients at younger age were at a higher risk of readmission. The morbidities including hypertension (OR=1.117, 95%CI: 1.054-1.184), hyperlipemia (OR=1.075, 95%CI: 1.009-1.146) and diabetes (OR=1.118, 95%CI: 1.053-1.188), gastrointestinal malignancies and peritoneal procedure significantly increased the risk of 30-day readmission in patients with MRA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>More than one in five patients with MRA was unplanned readmitted within 30-day follow-up. The above risk factors should be timely intervened and the corresponding medical care should be strengthened in patients with MRA to lessen the unplanned readmission and improve the readmission outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1409411","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:37:44Z","timestamp":1727771864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for early readmission to hospital in patients with malignancy-related ascites: a retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhenhua","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingbo","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMsa0803563","article-title":"Rehospitalizations among patients in the Medicare fee-for-service program","volume":"360","author":"Jencks","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","first-page":"1","article-title":"Higher readmissions at safety-net hospitals and potential policy solutions","volume":"34","author":"Berenson","year":"2012","journal-title":"Issue Brief (Commonw Fund)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1513024","article-title":"Readmissions, observation, and the hospital readmissions reduction program","volume":"374","author":"Zuckerman","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/1475-6773.12206","article-title":"The early effects of Medicare's mandatory hospital pay-for-performance program","volume":"50","author":"Ryan","year":"2015","journal-title":"Health Serv Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000228002.43688.c2","article-title":"Validation of the potentially avoidable hospital readmission rate as a routine indicator of the quality of hospital care","volume":"44","author":"Halfon","year":"2006","journal-title":"Med Care"},{"key":"B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J Gastrointest Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-288","article-title":"Role of Malignant ascites on human mesothelial cells and their gene expression profiles","volume":"14","author":"Matte","year":"2014","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","article-title":"Malignant ascites: pathophysiology and treatment","volume":"18","author":"Cavazzoni","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/clon.2002.0135","article-title":"The current and future management of Malignant ascites","volume":"15","author":"Smith","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24433","article-title":"Diagnosis and categorization of Malignant effusions: A 6-year review from a single academic institution","volume":"49","author":"Lew","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890801)64:3<753::aid-cncr2820640330>3.0.co;2-y","article-title":"Malignant ascites of unknown origin","volume":"64","author":"Ringenberg","year":"1989","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2021.02.004","article-title":"A palliative approach to management of peritoneal carcinomatosis and Malignant ascites","volume":"30","author":"Bleicher","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.04.013","article-title":"Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive Malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1","volume":"41","author":"Yamaguchi","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2013.12.001","article-title":"Non-cirrhotic ascites: pathophysiology, diagnosis and etiology","volume":"35","author":"Carrier","year":"2014","journal-title":"Rev Med Interne"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of Malignant ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198606000-00009","article-title":"Malignant ascites","volume":"203","author":"Garrison","year":"1986","journal-title":"Clin Exp observations. Ann Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl499","article-title":"Pattern and prognostic factors in patients with Malignant ascites: a retrospective study","volume":"18","author":"Ayantunde","year":"2007","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/1049909120928980","article-title":"Prevalence and inpatient hospital outcomes of Malignancy-related ascites in the United States","volume":"38","author":"Ramamoorthy","year":"2021","journal-title":"Am J Hosp Palliat Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.024","article-title":"Effect of frailty on postoperative readmissions and cost of care for ovarian cancer","volume":"159","author":"Sia","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25065","article-title":"The impact of a Malignant diagnosis on the pattern and outcome of readmission after liver and pancreatic surgery: An analysis of the nationwide readmissions database","volume":"117","author":"Bagante","year":"2018","journal-title":"J Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: an important clinical entity","volume":"11","author":"Salinas","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.5281","article-title":"Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials","volume":"29","author":"Blanke","year":"2011","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0194599820911727","article-title":"Presentation and outcomes of elderly patients undergoing head and neck surgeries: A national perspective","volume":"163","author":"Al-Qurayshi","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3393\/ac.2019.11.04","article-title":"Thirty-day readmission after elective colorectal surgery for colon cancer: A single-center cohort study","volume":"36","author":"Chung","year":"2020","journal-title":"Ann Coloproctol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.09.007","article-title":"Early readmission to hospital in patients with cancer with Malignant pleural effusions: analysis of the nationwide readmissions database","volume":"157","author":"Mitchell","year":"2020","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26137","article-title":"Readmissions after ovarian cancer cytoreduction surgery: The first 30 days and beyond","volume":"122","author":"Mardock","year":"2020","journal-title":"J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2020.07.103","article-title":"Risk factors for potentially avoidable readmissions following gynecologic oncology surgery","volume":"159","author":"Pyrzak","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2557-9","article-title":"A survey of treatment approaches of Malignant ascites in Germany and Austria","volume":"23","author":"Jehn","year":"2015","journal-title":"Support Care Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_606_18","article-title":"Therapeutic results of Denver percutaneous peritoneovenous shunt in cancer patients with Malignant ascites","volume":"16","author":"Tamagawa","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2015.12.014","article-title":"Therapeutic application of percutaneous peritoneovenous (Denver) shunt in treating chylous ascites in cancer patients","volume":"27","author":"Yarmohammadi","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0100-1","article-title":"Treatment of Malignant ascites using an automated pump device","volume":"113","author":"Storni","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1409411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T08:37:47Z","timestamp":1727771867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1409411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":33,"alternative-id":["10.3389\/fonc.2024.1409411"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1409411","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"1409411"}}